Sihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China

MT Newswires Live08-06

Sihuan Pharmaceutical Holdings Group (HKG:0460) gained the exclusive distribution rights for the CartiZol in China from South Korean Cellontech, a Tuesday filing with the Hong Kong Exchange said.

CartiZol is an intra-articular injection using collagen which strengthens, protects, and lubricates the joints and is used for the treatment of Osteoarthritis. It can reduce the effects of joint swelling and pain.

It absorbs shocks, reduces friction, and improves visco-elasticity of the joints. It also helps in the natural healing process of the joints by replenishing and coating the damaged cartilage tissues.

The company also obtained exclusive distribution rights for Cellontech Korea's porcine collagen medical aesthetic filler products in China in 2023. The porcine collagen being a de-immunogenic collagen, makes it the safest and most cost-effective collagen product.

The company's shares were up 6% on Tuesday's close.

Price (HKD): $0.53, Change: $+0.03, Percent Change: +6.00%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2457155410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-06 17:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2457155410","market":"hk","top_or_hot":-1,"title":"Sihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China","media":"MT Newswires Live","content":"<html><body><p> Sihuan Pharmaceutical Holdings Group (HKG:0460) gained the exclusive distribution rights for the CartiZol in China from South Korean Cellontech, a Tuesday filing with the Hong Kong Exchange said.</p><p>CartiZol is an intra-articular injection using collagen which strengthens, protects, and lubricates the joints and is used for the treatment of Osteoarthritis. It can reduce the effects of joint swelling and pain.</p><p>It absorbs shocks, reduces friction, and improves visco-elasticity of the joints. It also helps in the natural healing process of the joints by replenishing and coating the damaged cartilage tissues.</p><p>The company also obtained exclusive distribution rights for Cellontech Korea's porcine collagen medical aesthetic filler products in China in 2023. The porcine collagen being a de-immunogenic collagen, makes it the safest and most cost-effective collagen product.</p><p>The company's shares were up 6% on Tuesday's close.</p><p>Price (HKD): $0.53, Change: $+0.03, Percent Change: +6.00%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-06 17:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sihuan Pharmaceutical Holdings Group (HKG:0460) gained the exclusive distribution rights for the CartiZol in China from South Korean Cellontech, a Tuesday filing with the Hong Kong Exchange said....</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HKD","symbol_name":"尚乘数科","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2457155410","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457155410","pubTimestamp":1722938255,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sihuan Pharmaceutical Holdings Group  gained the exclusive distribution rights for the CartiZol in China from South Korean Cellontech, a Tuesday filing with the Hong Kong Exchange said.CartiZol is an intra-articular injection using collagen which strengthens, protects, and lubricates the joints and is used for the treatment of Osteoarthritis. It can reduce the effects of joint swelling and pain.It absorbs shocks, reduces friction, and improves visco-elasticity of the joints. It also helps in the natural healing process of the joints by replenishing and coating the damaged cartilage tissues.The company also obtained exclusive distribution rights for Cellontech Korea's porcine collagen medical aesthetic filler products in China in 2023. The porcine collagen being a de-immunogenic collagen, makes it the safest and most cost-effective collagen product.The company's shares were up 6% on Tuesday's close.Price : $0.53, Change: $+0.03, Percent Change: +6.00%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HKD":"尚乘数科","BK4526":"热门中概股","BK4588":"碎股","BK4023":"应用软件","BK1600":"工业大麻","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1515":"抗疫概念","BK1593":"医美概念股","00460":"四环医药"},"translate_title":"四环医药获得Cellontech韩国公司CartiZol中国独家经销权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"00460":0.9},"content_text":"Sihuan Pharmaceutical Holdings Group (HKG:0460) gained the exclusive distribution rights for the CartiZol in China from South Korean Cellontech, a Tuesday filing with the Hong Kong Exchange said.CartiZol is an intra-articular injection using collagen which strengthens, protects, and lubricates the joints and is used for the treatment of Osteoarthritis. It can reduce the effects of joint swelling and pain.It absorbs shocks, reduces friction, and improves visco-elasticity of the joints. It also helps in the natural healing process of the joints by replenishing and coating the damaged cartilage tissues.The company also obtained exclusive distribution rights for Cellontech Korea's porcine collagen medical aesthetic filler products in China in 2023. The porcine collagen being a de-immunogenic collagen, makes it the safest and most cost-effective collagen product.The company's shares were up 6% on Tuesday's close.Price (HKD): $0.53, Change: $+0.03, Percent Change: +6.00%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457155410"}